Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 20fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 15Cyclosporine 12Mycophenolic Acid 11Etoposide 9Busulfan 9Prednisone 8Vincristine 7Tacrolimus 7Filgrastim 7Carboplatin 7Bortezomib 7Antilymphocyte Serum 7Methotrexate 6Everolimus 6Doxorubicin 6Vorinostat 5Rituximab 5Gemcitabine 5Therapeutics 4Radiotherapy 4Panobinostat 4Paclitaxel 4Melphalan 4Lenalidomide 4Gene Expression Profiling 4Methylprednisolone 3MLN 8237 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoblastic Lymphadenopathy × Receptors, Chimeric Antigen × Clear all
NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡